GlassScriptPhysician profile
Gary W Raab
NPI 1972683001
$6,325.08
in general payments reported to CMS, 2019-2025
47 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $481 · 2021: $1,198 · 2022: $840 · 2023: $1,043 · 2024: $1,172 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196 · Education: $56.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.99 |
| Education | $56.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,305.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $946.54 | 2020-2025 | |
| Novo Nordisk INC | $644.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $389.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.76 | 2020-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $308.99 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Glaxosmithkline, LLC. | $256.67 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $247.85 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $246.81 | 2020-2025 | Jardiance, Emgality, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.02 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $162.01 | 2019-2024 | Xarelto |
| Abbott Laboratories | $139.10 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $138.11 | 2022-2024 | |
| Amarin Pharma, INC. | $80.16 | 2019-2022 | |
| Exact Sciences Corporation | $67.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Raab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.